RATIONALE: Peanut allergy is a life-threatening condition for which there is currently no cure. Immunotherapy using whole peanut preparations is hindered by risk of causing severe allergic reactions during treatment. PVX108 is a peptide-based immunotherapy being developed to treat peanut allergy without triggering allergic reactions during treatment. METHODS: PVX108 comprises a mixture of short, synthetic peptides derived from sequences of major peanut allergens, formulated for intradermal injection. Basophil reactivity to PVX108 was assessed using blood samples from peanut allergic donors. Safety and tolerability of PVX108 was assessed in a randomized, double-blind, placebo-controlled phase I trial in peanut-allergic adults. Cohorts were randomized 2:1 to receive PVX or placebo. The first eight cohorts received a single injection. The dose was escalated for each successive cohort upon safe completion of the prior cohort. The ninth cohort received six injections at the highest dose (150nmol) over 16 weeks. RESULTS: Basophil assays confirmed lack of basophil reactivity to PVX108 in contrast to peanut extract in 146 peanut-allergic donors. The phase I trial enrolled a total of 66 subjects. There were no serious adverse events. Adverse events considered possibly or probably related to treatment were graded mild or moderate, with the majority being transient injection site reactions. None was deemed of clinical concern by the study Safety Review Committee. There was no relationship between dose level and frequency or severity of adverse events. CONCLUSIONS: Basophil reactivity and phase I data demonstrate that PVX108 has a highly favourable safety profile for treatment of peanut allergic individuals, including those with severe allergy. RATIONALE: Adrenaline auto-injector (AAI) dispensing data, a community-based proxy for number of individuals at risk of anaphylaxis, will provide complementary information on anaphylaxis risk in addition to hospital admission data. We examined trends of AAI dispensing in Australia over a 10 year-period (January 2005 to December 2014) and compared the prescription trends of dispensed AAI by different speciality of prescriber. METHODS: Patients with AAI were identified from a 10% random sample of Australian Pharmaceutical Benefits Scheme (PBS) data. PBS is the Australian national drug subsidy program. Cumulative incidence and incidence rates of patients with AAI were calculated using Australian population data. RESULTS: The cumulative incidence of patients with AAI in 2005-2014 was 75.43 per 100,000 person-years (95%CI 75.07-75.80). Males and children were more likely to be prescribed an AAI compared with females and adults. An increasing incidence rate was observed among the total population from 2005 to 2014 (from 71.47 to 82.07 per 100,000 personyears, P<0.001) although the magnitude of this increase varied by state. In most regions of Australia, there was a shift towards more prescriptions being provided by general practitioners (GP) and fewer provided by specialists such as allergists. Children (0-19 years) were more likely to be prescribed AAI by specialists and adults by a GP. CONCLUSIONS: Overall, an increase in AAI dispensing was observed between 2005 and 2014. The rising number of AAI prescribed by GPs compared with specialists reflects how the Australian healthcare system has responded to the increased burden of anaphylaxis, providing evidence of a decentralisation of healthcare services.
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RATIONALE:
The contribution of the innate immune system in the development of pediatric food allergy is increasingly clear. We have recently reported that monocytes from infants with egg allergy circulate in greater frequency and express higher levels of activation markers relative to monocytes from non-allergic infants. We have also shown that the non-T cell fraction of blood from infants with egg allergy produce higher levels of pro-inflammatory cytokines following stimulation with lipopolysaccharide (LPS) compared to non-allergic infants. These features mirror the defining signature of trained innate immunity (TRIM), raising the possibility that TRIM plays a role in food allergy pathogenesis. METHODS: This study used peripheral blood mononuclear cells (PBMCs) from a population-based cohort of challenge-confirmed food allergic and healthy infants to quantify the functional role of monocytes in the Th2 immune response associated with food allergy and further elucidate the role of TRIM in the development of food allergy. RESULTS: We show that purified blood monocytes from infants with food allergy produce more of the granulocyte recruiting factors CCL2, CCL3 and CCL5 following LPS stimulation relative to non-allergic infants. We also show that food allergic infants have higher monocyte:CD4 T cell ratios than non-allergic infants, and that activated monocytes from food allergic children can skew na€ ıve CD4 T cells towards a Th2 phenotype. CONCLUSIONS: Monocytes from food allergic children are programmed to a hyper-inflammatory phenotype that may have downstream consequences for T cells. Food allergy is potentially associated with aberrant trained innate immunity in early life.
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